Log In
person
Alnylam Pharmaceuticals Inc
ALNY
summarize
3 total product lines
calendar_month
Revenue as of 12/31/2023
| Reporting Segmentarrow_drop_up | Product Line | Amount (USD) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (USD) | Percentage |
| RNAi Therapeutics |
Branded Pharmaceuticals
These companies research, develop, and manufacture patented drugs.
|
1.24B | 67.90% |
| RNAi Therapeutics |
Pre-Revenue Pharmaceuticals
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
0.55B | 29.87% |
| RNAi Therapeutics |
Pharmaceutical Patent Licensing
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
0.04B | 2.22% |
| keyboard_arrow_down |
RNAi Therapeutics
Branded Pharmaceuticals
|
1.24B | 67.90% |
| keyboard_arrow_right |
These companies research, develop, and manufacture patented drugs.
|
||
| keyboard_arrow_down |
RNAi Therapeutics
Pre-Revenue Pharmaceuticals
|
0.55B | 29.87% |
| keyboard_arrow_right |
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
||
| keyboard_arrow_down |
RNAi Therapeutics
Pharmaceutical Patent Licensing
|
0.04B | 2.22% |
| keyboard_arrow_right |
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
||